Crinetics Pharmaceuticals stock exits Nasdaq after USD 85.00 deal

Crinetics Pharmaceuticals stock exited public trading after each share was converted into USD 85.00 in cash under the completed Vertex merger. The transaction became effective on September 1, 2026, ending Crinetics' status as an independent Nasdaq-listed company.

Vertex takes full control

Vertex said the acquisition closed on September 1, 2026, after regulatory clearances and approval by Crinetics shareholders. The buyer described the transaction as carrying a USD 10.0 billion total equity value and USD 8.8 billion net of estimated cash acquired.

The merger changed the stock's status more decisively than a normal takeover announcement. Crinetics requested suspension of trading on Nasdaq, began delisting and deregistration steps, and converted outstanding common shares into merger consideration, according to The Globe and Mail.

Quarterly revenue surged

Before the takeover closed, Crinetics reported second-quarter 2026 revenue of USD 25.12 million, compared with analyst estimates of USD 14.84 million. Revenue therefore exceeded the estimate by USD 10.28 million, while year-over-year growth reached 2,336.9 percent, according to MarketBeat.

Adjusted earnings were still negative in the quarter. Crinetics reported a loss of USD 1.14 per share versus a consensus loss of USD 1.18, a USD 0.04 beat, while the year-earlier loss was USD 1.23 per share.

USD 85.00 sets the final value

The merger consideration fixes the final cash value at USD 85.00 for each Crinetics share. A September 1, 2026 filing described the effective merger date and the conversion of common stock into cash consideration, ending the public-market trading history of CRNX.